Herpesvirus encephalitis following herpes keratitis.
D000927:Anticonvulsants / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D001921:Brain / Q000382:microbiology; D003561:Cytarabine / Q000627:therapeutic use; D004660:Encephalitis / Q000150:complications / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005158:Facial Paralysis / Q000209:etiology; D005260:Female; D005334:Fever / Q000209:etiology; D006429:Hemiplegia / Q000209:etiology; D006566:Herpesviridae Infections / Q000209:etiology* / Q000276:immunology; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007223:Infant; D008607:Intellectual Disability / Q000209:etiology; D007635:Keratitis, Dendritic / Q000150:complications* / Q000188:drug therapy; D007806:Language Disorders / Q000209:etiology; D009500:Neutralization Tests; D012640:Seizures / Q000209:etiology; D018139:Simplexvirus / Q000302:isolation & purification; D013702:Temporal Lobe / Q000473:pathology
D000927:Anticonvulsants; D003561:Cytarabine; D001285:Atropine; D007065:Idoxuridine